Richard Titball

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2472229/publications.pdf

Version: 2024-02-01

120 papers	8,593 citations	36203 51 h-index	48187 88 g-index
123 all docs	123 docs citations	123 times ranked	6577 citing authors

#	Article	IF	Citations
1	The increased prevalence of Vibrio species and the first reporting of Vibrio jasicida and Vibrio rotiferianus at UK shellfish sites. Water Research, 2022, 211, 117942.	5.3	26
2	The rapid progress in COVID vaccine development and implementation. Npj Vaccines, 2022, 7, 20.	2.9	15
3	Bacterial dormancy: A subpopulation of viable but non-culturable cells demonstrates better fitness for revival. PLoS Pathogens, 2021, 17, e1009194.	2.1	37
4	Correlating Genotyping Data of Coxiella burnetii with Genomic Groups. Pathogens, 2021, 10, 604.	1.2	14
5	Functional redundancy of Burkholderia pseudomallei phospholipase C enzymes and their role in virulence. Scientific Reports, 2020, 10, 19242.	1.6	6
6	Campylobacter jejuni 11168H Exposed to Penicillin Forms Persister Cells and Cells With Altered Redox Protein Activity. Frontiers in Cellular and Infection Microbiology, 2020, 10, 565975.	1.8	7
7	Coxiella burnetii replicates in Galleria mellonella hemocytes and transcriptome mapping reveals in vivo regulated genes. Virulence, 2020, 11, 1268-1278.	1.8	9
8	Trehalose and bacterial virulence. Virulence, 2020, 11, 1192-1202.	1.8	58
9	Isolation and primary culture of Galleria mellonella hemocytes for infection studies. F1000Research, 2020, 9, 1392.	0.8	9
10	Isolation and primary culture of Galleria mellonella hemocytes for infection studies. F1000Research, 2020, 9, 1392.	0.8	11
11	Clostridium perfringens epsilon toxin vaccine candidate lacking toxicity to cells expressing myelin and lymphocyte protein. Npj Vaccines, 2019, 4, 32.	2.9	8
12	The global impact and cost-effectiveness of a melioidosis vaccine. BMC Medicine, 2019, 17, 129.	2.3	11
13	Burkholderia thailandensis strain E555 is a surrogate for the investigation of Burkholderia pseudomallei replication and survival in macrophages. BMC Microbiology, 2019, 19, 97.	1.3	23
14	Extensive genome analysis of Coxiella burnetii reveals limited evolution within genomic groups. BMC Genomics, 2019, 20, 441.	1.2	31
15	The pore structure of Clostridium perfringens epsilon toxin. Nature Communications, 2019, 10, 2641.	5.8	44
16	Clostridium perfringens Epsilon Toxin Compromises the Blood-Brain Barrier in a Humanized Zebrafish Model. IScience, 2019, 15, 39-54.	1.9	10
17	Novel multi-component vaccine approaches for Burkholderia pseudomallei. Clinical and Experimental Immunology, 2019, 196, 178-188.	1.1	28
18	Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 653-660.	1.4	46

#	Article	IF	Citations
19	From cell culture to cynomolgus macaque: infection models show lineage-specific virulence potential of Coxiella burnetii. Journal of Medical Microbiology, 2019, 68, 1419-1430.	0.7	13
20	Galleria mellonella larvae allow the discrimination of toxic and non-toxic chemicals. Chemosphere, 2018, 198, 469-472.	4.2	79
21	Galleria mellonella as an infection model to investigate virulence of Vibrio parahaemolyticus. Virulence, 2018, 9, 197-207.	1.8	43
22	Standardization of G. mellonella Larvae to Provide Reliable and Reproducible Results in the Study of Fungal Pathogens. Journal of Fungi (Basel, Switzerland), 2018, 4, 108.	1.5	43
23	The molecular basis of protein toxin HicAâ€“dependent binding of the protein antitoxin HicB to DNA. Journal of Biological Chemistry, 2018, 293, 19429-19440.	1.6	10
24	Trehalase plays a role in macrophage colonization and virulence ofBurkholderia pseudomalleiin insect and mammalian hosts. Virulence, 2017, 8, 30-40.	1.8	30
25	Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials?. Vaccine, 2017, 35, 5981-5989.	1.7	84
26	A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth. Microbial Pathogenesis, 2017, 107, 175-180.	1.3	7
27	Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei. Vaccine Journal, 2017, 24, .	3.2	46
28	A Noise Trimming and Positional Significance of Transposon Insertion System to Identify Essential Genes in Yersinia pestis. Scientific Reports, 2017, 7, 41923.	1.6	8
29	An integrated computational-experimental approach reveals Yersinia pestis genes essential across a narrow or a broad range of environmental conditions. BMC Microbiology, 2017, 17, 163.	1.3	16
30	Galleria mellonellaas a model host for microbiological and toxin research. Virulence, 2016, 7, 840-845.	1.8	95
31	Protection against Experimental Melioidosis with a Synthetic manno-Heptopyranose Hexasaccharide Glycoconjugate. Bioconjugate Chemistry, 2016, 27, 1435-1446.	1.8	36
32	Variable protection against experimental broiler necrotic enteritis after immunization with the C-terminal fragment ofClostridium perfringensalpha-toxin and a non-toxic NetB variant. Avian Pathology, 2016, 45, 381-388.	0.8	20
33	Burkholderia pseudomallei kynB plays a role in AQ production, biofilm formation, bacterial swarming and persistence. Research in Microbiology, 2016, 167, 159-167.	1.0	18
34	Immunisation with proteins expressed during chronic murine melioidosis provides enhanced protection against disease. Vaccine, 2016, 34, 1665-1671.	1.7	27
35	Functional Analysis of the Role of Toxinâ€“Antitoxin (TA) Loci in Bacterial Persistence. Methods in Molecular Biology, 2016, 1333, 121-129.	0.4	10
36	Macroautophagy is essential for killing of intracellularBurkholderia pseudomalleiin human neutrophils. Autophagy, 2015, 11, 748-755.	4.3	27

#	Article	IF	Citations
37	Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine, 2015, 33, 686-692.	1.7	59
38	A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 447-456.	1.7	79
39	From crystal structure to inÂsilico epitope discovery in the BurkholderiaÂpseudomallei flagellar hookâ€associated protein FlgK. FEBS Journal, 2015, 282, 1319-1333.	2.2	42
40	Structure-Based Design of a B Cell Antigen from B. pseudomallei. ACS Chemical Biology, 2015, 10, 803-812.	1.6	12
41	Burkholderia pseudomallei sequencing identifies genomic clades with distinct recombination, accessory, and epigenetic profiles. Genome Research, 2015, 25, 129-141.	2.4	61
42	Genome-Wide Saturation Mutagenesis of Burkholderia pseudomallei K96243 Predicts Essential Genes and Novel Targets for Antimicrobial Development. MBio, 2014, 5, e00926-13.	1.8	75
43	The HicA toxin from Burkholderia pseudomallei has a role in persister cell formation. Biochemical Journal, 2014, 459, 333-344.	1.7	81
44	Identification of a Key Residue for Oligomerisation and Pore-Formation of Clostridium perfringens NetB. Toxins, 2014, 6, 1049-1061.	1.5	13
45	Bacterial Drug Tolerance under Clinical Conditions Is Governed by Anaerobic Adaptation but not Anaerobic Respiration. Antimicrobial Agents and Chemotherapy, 2014, 58, 5775-5783.	1.4	31
46	Differences in carbon source utilisation distinguish Campylobacter jejuni from Campylobacter coli. BMC Microbiology, 2014, 14, 262.	1.3	30
47	Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein Conjugate. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	25
48	Influence of the molybdenum cofactor biosynthesis on anaerobic respiration, biofilm formation and motility in Burkholderia thailandensis. Research in Microbiology, 2014, 165, 41-49.	1.0	20
49	Clostridium perfringens epsilon toxin mutant Y30A-Y196A as a recombinant vaccine candidate against enterotoxemia. Vaccine, 2014, 32, 2682-2687.	1.7	36
50	The Twin Arginine Translocation System Is Essential for Aerobic Growth and Full Virulence of Burkholderia thailandensis. Journal of Bacteriology, 2014, 196, 407-416.	1.0	13
51	Exploiting the Burkholderia pseudomallei Acute Phase Antigen BPSL2765 for Structure-Based Epitope Discovery/Design in Structural Vaccinology. Chemistry and Biology, 2013, 20, 1147-1156.	6.2	50
52	Protection against avian necrotic enteritis after immunisation with NetB genetic or formaldehyde toxoids. Vaccine, 2013, 31, 4003-4008.	1.7	56
53	Identification of type II toxin-antitoxin modules inBurkholderia pseudomallei. FEMS Microbiology Letters, 2013, 338, 86-94.	0.7	17
54	Molecular Architecture and Functional Analysis of NetB, a Pore-forming Toxin from Clostridium perfringens. Journal of Biological Chemistry, 2013, 288, 3512-3522.	1.6	90

#	Article	IF	Citations
55	Clostridium perfringens epsilon toxin H149A mutant as a platform for receptor binding studies. Protein Science, 2013, 22, 650-659.	3.1	40
56	Galleria mellonella as a model system to test the pharmacokinetics and efficacy of antibiotics against Burkholderia pseudomallei. International Journal of Antimicrobial Agents, 2013, 41, 330-336.	1.1	59
57	The Condition-Dependent Transcriptional Landscape of Burkholderia pseudomallei. PLoS Genetics, 2013, 9, e1003795.	1.5	81
58	Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes. PLoS Neglected Tropical Diseases, 2012, 6, e1488.	1.3	94
59	Role of RelA and SpoT in Burkholderia pseudomallei Virulence and Immunity. Infection and Immunity, 2012, 80, 3247-3255.	1.0	35
60	Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity. Vaccine, 2012, 30, 6777-6782.	1.7	56
61	Low-Dose Exposure of C57BL/6 Mice to Burkholderia pseudomallei Mimics Chronic Human Melioidosis. American Journal of Pathology, 2011, 179, 270-280.	1.9	51
62	Development of Vaccines Against Burkholderia Pseudomallei. Frontiers in Microbiology, 2011, 2, 198.	1.5	70
63	Molecular basis of toxicity of Clostridiumâ€ƒperfringens epsilon toxin. FEBS Journal, 2011, 278, 4589-4601.	2.2	95
64	Combining Vaccination and Postexposure CpG Therapy Provides Optimal Protection Against Lethal Sepsis in a Biodefense Model of Human Melioidosis. Journal of Infectious Diseases, 2011, 204, 636-644.	1.9	24
65	Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis. BMC Microbiology, 2011, 11, 11.	1.3	132
66	Superoxide dismutase C is required for intracellular survival and virulence of Burkholderia pseudomallei. Microbiology (United Kingdom), 2011, 157, 2392-2400.	0.7	46
67	Human Immune Responses to Burkholderia pseudomallei Characterized by Protein Microarray Analysis. Journal of Infectious Diseases, 2011, 203, 1002-1011.	1.9	62
68	Flagellar Glycosylation in Burkholderia pseudomallei and Burkholderia thailandensis. Journal of Bacteriology, 2011, 193, 3577-3587.	1.0	43
69	Burkholderia pseudomalleiProteins Presented by Monocyte-Derived Dendritic Cells Stimulate Human Memory T CellsIn Vitro. Infection and Immunity, 2011, 79, 305-313.	1.0	21
70	Progress toward development of vaccines against melioidosis: A review. Clinical Therapeutics, 2010, 32, 1437-1445.	1.1	49
71	Insect Infection Model forCampylobacter jejuniReveals ThatOâ€methyl Phosphoramidate Has Insecticidal Activity. Journal of Infectious Diseases, 2010, 201, 100129142112076-000.	1.9	72
72	Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine, 2010, 28, 7551-7555.	1.7	38

#	Article	IF	Citations
73	Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology (United Kingdom), 2009, 155, 1516-1522.	0.7	91
74	Phenotypic and Functional Characterization of Human Memory T Cell Responses to Burkholderia pseudomallei. PLoS Neglected Tropical Diseases, 2009, 3, e407.	1.3	53
75	Rethinking our understanding of the pathogenesis of necrotic enteritis in chickens. Trends in Microbiology, 2009, 17, 32-36.	3.5	259
76	Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. Vaccine, 2009, 27, 4447-4451.	1.7	46
77	Clostridium perfringens vaccines. Vaccine, 2009, 27, D44-D47.	1.7	51
78	A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13499-13504.	3.3	171
79	Burkholderia pseudomallei: animal models of infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, S111-S116.	0.7	67
80	Vaccines against intracellular bacterial pathogens. Drug Discovery Today, 2008, 13, 596-600.	3.2	60
81	RecombinantBacillus subtilisExpressing theClostridium perfringensAlpha Toxoid Is a Candidate Orally Delivered Vaccine against Necrotic Enteritis. Infection and Immunity, 2008, 76, 5257-5265.	1.0	81
82	A 55 kDa hypothetical membrane protein is an iron-regulated virulence factor of Francisella tularensis subsp. novicida U112. Journal of Medical Microbiology, 2007, 56, 1268-1276.	0.7	23
83	Polysaccharides and virulence of Burkholderia pseudomallei. Journal of Medical Microbiology, 2007, 56, 1005-1010.	0.7	48
84	Identification of a LolC Homologue in Burkholderia pseudomallei , a Novel Protective Antigen for Melioidosis. Infection and Immunity, 2007, 75, 4173-4180.	1.0	57
85	Development of Signature-Tagged Mutagenesis in Burkholderia pseudomallei To Identify Genes Important in Survival and Pathogenesis. Infection and Immunity, 2007, 75, 1186-1195.	1.0	96
86	The identification of surface proteins of Burkholderia pseudomallei. Vaccine, 2007, 25, 2664-2672.	1.7	52
87	Analysis of peptide mimotopes of Burkholderia pseudomallei exopolysaccharide. Vaccine, 2007, 25, 7796-7805.	1.7	12
88	Analysis of protection afforded by a Clostridium perfringens Î±-toxoid against heterologous clostridial phospholipases C. Microbial Pathogenesis, 2007, 43, 161-165.	1.3	18
89	Role of T Cells in Innate and Adaptive Immunity against MurineBurkholderia pseudomalleiInfection. Journal of Infectious Diseases, 2006, 193, 370-379.	1.9	109
90	Adammutant ofYersinia pestisis attenuated and induces protection against plague. FEMS Microbiology Letters, 2005, 252, 251-256.	0.7	61

#	Article	IF	Citations
91	Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. Microbiology (United Kingdom), 2005, 151, 1919-1926.	0.7	79
92	Immunization with the Câ€Domain of Î±â€Toxin Prevents Lethal Infection, Localizes Tissue Injury, and Promotes Host Response to Challenge withClostridium perfringens. Journal of Infectious Diseases, 2004, 190, 767-773.	1.9	77
93	Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology (United Kingdom), 2004, 150, 2669-2676.	0.7	172
94	Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. Journal of Medical Microbiology, 2004, 53, 1177-1182.	0.7	116
95	Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14240-14245.	3.3	675
96	Age influences resistance ofCaenorhabditis elegansto killing by pathogenic bacteria. FEMS Microbiology Letters, 2004, 234, 281-287.	0.7	40
97	Clostridium perfringens Îµ-toxin shows structural similarity to the pore-forming toxin aerolysin. Nature Structural and Molecular Biology, 2004, 11, 797-798.	3.6	171
98	Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. Journal of Medical Microbiology, 2003, 52, 845-851.	0.7	77
99	A Mutant of Burkholderia pseudomallei, Auxotrophic in the Branched Chain Amino Acid Biosynthetic Pathway, Is Attenuated and Protective in a Murine Model of Melioidosis. Infection and Immunity, 2002, 70, 5290-5294.	1.0	112
100	Role of trehalose biosynthesis in environmental survival and virulence of Salmonella enterica serovar typhimurium. Research in Microbiology, 2002, 153, 281-287.	1.0	31
101	Salmonellavaccines for use in humans: present and future perspectives. FEMS Microbiology Reviews, 2002, 26, 339-353.	3.9	103
102	Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. Journal of Medical Microbiology, 2002, 51, 539-553.	0.7	93
103	Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine, 2001, 19, 4465-4472.	1.7	154
104	Genome sequence of Yersinia pestis, the causative agent of plague. Nature, 2001, 413, 523-527.	13.7	1,144
105	Stabilisation of Salmonella vaccine vectors by the induction of trehalose biosynthesis. Vaccine, 2000, 19, 1239-1245.	1.7	16
106	An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clinical and Experimental Immunology, 1999, 116, 107-114.	1.1	133
107	Recombinant Vaccinia Viruses Protect AgainstClostridium perfringensÎ±-Toxin. Viral Immunology, 1999, 12, 97-105.	0.6	24
108	Characterisation of the calcium-binding C-terminal domain of Clostridium perfringens alpha-toxin 1 1Edited by A Klug. Journal of Molecular Biology, 1999, 294, 757-770.	2.0	63

#	Article	IF	Citations
109	Structure of the key toxin in gas gangrene. Nature Structural and Molecular Biology, 1998, 5, 738-746.	3.6	174
110	Macromolecular organisation of recombinantYersinia pestisF1 antigen and the effect of structure on immunogenicity. FEMS Immunology and Medical Microbiology, 1998, 21, 213-221.	2.7	64
111	UDP-glucose Deficiency Causes Hypersensitivity to the Cytotoxic Effect of Clostridium perfringens Phospholipase C. Journal of Biological Chemistry, 1998, 273, 24433-24438.	1.6	37
112	Production of a non-toxic site-directed mutant of Clostridium perfringens Îµ-toxin which induces protective immunity in mice. Microbiology (United Kingdom), 1998, 144, 333-341.	0.7	61
113	A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine, 1997, 15, 1079-1084.	1.7	143
114	Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infection and Immunity, 1997, 65, 1926-1930.	1.0	83
115	Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine, 1996, 14, 1613-1619.	1.7	55
116	Molecular variation between the Î±-toxins from the type strain (NCTC 8237) and clinical isolates of Clostridium perfringens associated with disease in man and animals. Microbiology (United Kingdom), 1996, 142, 191-198.	0.7	45
117	A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunology and Medical Microbiology, 1995, 12, 223-230.	2.7	205
118	Efficient generation of a reshaped human mAb specific for the Î± toxin of Clostridium perfringens. Protein Engineering, Design and Selection, 1994, 7, 1501-1507.	1.0	5
119	Biochemical and immunological properties of the C-terminal domain of the alpha-toxin ofClostridium perfringens. FEMS Microbiology Letters, 1993, 110, 45-50.	0.7	68
120	A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene. Vaccine, 1993, 11, 1253-1258.	1.7	151